Company intelligence / Profile preview

Oxagen

Milton Park / Abingdon, Oxfordshire/England, United Kingdomoxygen.com ↗

Ownership: Private
Employees: ~75
Development stage: Other

Overview

Oxagen was a UK-based biotechnology company specializing in the identification of novel drug targets using human genetics, with a particular emphasis on inflammatory diseases and women’s health. The company advanced several programs into preclinical and early clinical development but did not bring any products to market before ceasing operations.

Therapeutic areas: Women's HealthEndocrinologyImmunology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

ATX-2286

Preclinical

Partnerships

Historically partnered with major pharmaceutical companies such as Schering AG for osteoporosis research.

Beyond the preview

Go deeper on Oxagen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxagen.

Explore the full profile